SYnabs & Biokit announce strategic collaboration on valproic acid antigen -- MEDICA - World Forum for Medicine

08.10.2020

SYnAbs S.A.

SYnabs & Biokit announce strategic collaboration on valproic acid antigen

SYnAbs & Biokit, A Werfen Company are proud to announce their success in the development of the best anti-valproic acid monoclonal antibody of the market! This case study is a new proof of the high efficiency of SYnAbs technologies for the generation of antibodies against haptens.

Exhibitor Data Sheet